INNOVATIVE SOLUTIONS TO IMPROVE QUALITY OF CARE
Jen Stevens, of Edinburgh, Scotland, was fortunate that her doctors were using Abbott’s ARCHITECT STAT High Sensitive Troponin-I test.

**QUICK RESULTS, EFFECTIVE TREATMENT**
When Jen first started experiencing chest pains, she attributed them to stress and tried to carry on with her day. When the pain got worse, her colleagues called an ambulance. Doctors used Abbott’s test to measure her level of troponin — a protein that shows up in blood when the heart muscle has been damaged — to determine that she was, in fact, having a heart attack. Quick treatment set her firmly on the road to recovery and, today, she’s enjoying a full, healthy life with her daughters.

**A TRADITION OF LEADERSHIP**
Through the years, Abbott has built a broad and innovative portfolio of sophisticated technologies that screen and diagnose disease as well as monitor general health. The new systems we’re launching over the next few years — including solutions across Clinical Chemistry, Immunoassay, Hematology, Blood and Plasma Screening, Molecular Diagnostics, and Point of Care — are the natural extension of our commitment to customer-focused innovation.

Abbott’s test can help rapidly diagnose and triage chest-pain patients, allowing timely action and helping to improve patient outcomes.
2016 BUSINESS HIGHLIGHTS

- **iSTAT Alinity**, Abbott’s next-generation handheld system, which is designed to be the world’s easiest-to-use with-patient testing device, was approved in Europe

- Launched **AlinIQ**, a first-of-its-kind professional services and informatics solution designed to improve laboratory productivity

- Abbott’s **ZIKA** molecular diagnostics test received Emergency Use Authorization from the U.S. Food and Drug Administration

- Abbott’s **RealTime HIV-1** quantitative assay received CE mark for dried-blood-spot testing and was accepted for the World Health Organization’s list of pre-qualified diagnostics

- Academic research on Abbott’s **ARCHITECT STAT High Sensitive Troponin-I** test found that it helped predict risk of heart attack and death, as well as response to statin medications

- Launched new Vitamin D and syphilis assays for **ARCHITECT** in the United States
Alignment, Innovation, Unity: Alinity

Over the next few years, Abbott will revolutionize the diagnostics industry by bringing our customers an integrated family of systems spanning Immunoassay and Clinical Chemistry, Blood Screening, Hematology, Point of Care, Molecular testing and Informatics.

Our new platforms represent a major leap forward over competitive systems in terms of reliability, cost, capacity, space efficiency, and ease of use.